Candidates for drug repurposing to address the cognitive symptoms in schizophrenia
- 11 September 2022
- journal article
- research article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 120, 110637
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institutes of Health (R01MH118281, R56AG061163)
- Vetenskapsrådet (2017-03011)
This publication has 94 references indexed in Scilit:
- Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapyJournal of Neuroinflammation, 2013
- Role of Melatonin in SchizophreniaInternational Journal of Molecular Sciences, 2013
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophreniaSchizophrenia Research, 2011
- The treatment of cognitive impairment in schizophreniaPharmacology Biochemistry and Behavior, 2011
- Does sumatriptan cross the blood–brain barrier in animals and man?The Journal of Headache and Pain, 2009
- Walking the Interactome for Prioritization of Candidate Disease GenesThe American Journal of Human Genetics, 2008
- Gene Expression in the Etiology of SchizophreniaSchizophrenia Bulletin, 2007
- Network biology: understanding the cell's functional organizationNature Reviews Genetics, 2004
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003